Stockreport

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia [Yahoo! Finance]

MiNK Therapeutics, Inc.  (INKT) 
PDF Findings extend MiNK's iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a large unmet-need market LEXINGTON, Mass., [Read more]